EE47 Cost Per Recurrence-Free Survivor (CPRS) and Cost Per Recurrence-Free Life Month (CPRLM) of Adjuvant Nivolumab (NIVO) Versus Pembrolizumab (PEMBRO) Among Patients With Resected Stage IIB/IIC Melanoma
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.348
https://www.valueinhealthjournal.com/article/S1098-3015(24)00463-7/fulltext
Title :
EE47 Cost Per Recurrence-Free Survivor (CPRS) and Cost Per Recurrence-Free Life Month (CPRLM) of Adjuvant Nivolumab (NIVO) Versus Pembrolizumab (PEMBRO) Among Patients With Resected Stage IIB/IIC Melanoma
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00463-7&doi=10.1016/j.jval.2024.03.348
First page :
Section Title :
Open access? :
No
Section Order :
11692